Road to Retirement: Medicare Basics - Part D Prescription Coverage

The most significant recent shift in Medicare Part D prescription drug coverage took effect on January 1, 2026: negotiated lower prices for the first 10 high-cost drugs selected under the Inflation Reduction Act of 2022 now apply. This marks the first time Medicare has directly negotiated prices with manufacturers, a power granted by the IRA after decades without it. The drugs target serious conditions including cancer, diabetes, blood clots, heart failure, autoimmune disorders, and chronic kidney disease, with many seeing discounts of at least 38% from 2023 list prices. These reductions are expected to cut beneficiary out-of-pocket spending by billions annually and save Medicare roughly $6 billion per year on these medications alone.

Layered on this, the annual out-of-pocket cap for Part D—set at $2,000 in 2025—rose to $2,100 in 2026 to account for inflation. Beneficiaries pay nothing for covered Part D drugs after reaching this limit in deductibles, copays, and coinsurance for the rest of the year. The maximum plan deductible increased modestly to $615, though some plans offer lower or no deductibles. These build on the IRA's overhaul, which removed the coverage gap in 2025 and shifted more liability to plans and manufacturers in catastrophic phases.

For the more than 50 million people enrolled in Part D, the impact hits hardest among those with chronic conditions reliant on costly drugs. The negotiated prices deliver tangible savings for users of the 10 selected medications, while the cap protects against ruinous expenses that once threatened even insured seniors. Market dynamics add complexity: standalone Part D plans fell 22% from 2025 (to about 360 nationwide), potentially limiting options, and premiums have varied amid efforts to stabilize them. The ongoing Medicare Prescription Payment Plan helps by letting enrollees spread costs monthly rather than paying large sums at the pharmacy.

All trace back to the IRA's staged rollout, making 2026 a landmark year for price negotiation's start and the maturation of new cost safeguards.